ArtivionAORT
AORT
About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
Employees: 1,500
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,252% more call options, than puts
Call options by funds: $892K | Put options by funds: $66K
13% more capital invested
Capital invested by funds: $964M [Q3] → $1.09B (+$127M) [Q4]
4.55% more ownership
Funds ownership: 86.43% [Q3] → 90.98% (+4.55%) [Q4]
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
1% more funds holding
Funds holding: 172 [Q3] → 173 (+1) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 58
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
17%
upside
Avg. target
$34
19%
upside
High target
$34
20%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target | 20%upside $34 | Buy Reiterated | 28 Jan 2025 |
JMP Securities Daniel Stauder 67% 1-year accuracy 4 / 6 met price target | 17%upside $33 | Market Outperform Reiterated | 10 Dec 2024 |
Financial journalist opinion
Based on 3 articles about AORT published over the past 30 days
Neutral
PRNewsWire
1 week ago
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results
ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Positive
Investors Business Daily
2 weeks ago
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Neutral
PRNewsWire
3 weeks ago
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation.
Positive
Zacks Investment Research
1 month ago
Best Momentum Stocks to Buy for January 7th
NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for January 7th
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024.
Negative
TechCrunch
2 months ago
US medical device giant Artivion says hackers stole files during cybersecurity incident
Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident.
Neutral
PRNewsWire
2 months ago
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.
Neutral
Seeking Alpha
3 months ago
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Daniel Stauder - JMP Securities Suraj Kalia - Oppenheimer Nelson Cox - Lake Street Capital Mike Matson - Needham & Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Third Quarter 2024 Financial Conference Call. At this time, all participants are in listen only mode.
Positive
Zacks Investment Research
3 months ago
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Neutral
PRNewsWire
3 months ago
Artivion Reports Third Quarter 2024 Financial Results
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China. Commercialization expected in the second half of 2025.
Charts implemented using Lightweight Charts™